BioMedTracker is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Informa
Menu

Report Library

All Reports
Datamonitor Healthcare Strategy: Immuno-Oncology Deal Trends, 2014–18

August 05, 2019

  • Cancer research and treatment has evolved considerably over recent years, and one of the most promising modalities to emerge is immuno-oncology.
  • Arguably one of the greatest breakthroughs in modern medicine, immuno-oncology essentially unlocks the breaks on the body's natural ability to attack and fight off cancer.
  • Immuno-oncology therapeutics help to reprogram the immune system so that it recognizes and destroys cancer cells, which under normal circumstances may be able to evade an immune system attack.
  • Pharmaceutical companies are pursuing several types of immuno-oncology products, including checkpoint inhibitors, tumor necrosis factor receptor agonists, adoptive T-cell therapies such as chimeric antigen receptor T-cell (CAR-T) technology, tumor-infiltrating lymphocytes, and vaccines.
  • As of July 2019, there are 25 immuno-oncology therapies (including monotherapies and combinations with chemotherapies or other products, but excluding biosimilars) launched throughout the world for a wide range of solid and hematological tumors.

    This Datamonitor Healthcare report contains a Strategy module.
    Disease Group Covered: Oncology
  • Back to the top Back to the top